Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $16.0 down -1.23% from its previous closing price of $16.2. In other words, the price has decreased by -$1.23 from its previous closing price. On the day, 1.19 million shares were traded. AVDL stock price reached its highest trading level at $16.37 during the session, while it also had its lowest trading level at $15.99.
Ratios:
For a deeper understanding of Avadel Pharmaceuticals plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 263.77. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.41.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on September 03, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $16.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1572981760 and an Enterprise Value of 1510058240. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.03 while its Price-to-Book (P/B) ratio in mrq is 17.07. Its current Enterprise Value per Revenue stands at 6.831 whereas that against EBITDA is 4241.737.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.47, which has changed by 0.25195622 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $16.66, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 19.99%, while the 200-Day Moving Average is calculated to be 60.52%.
Shares Statistics:
For the past three months, AVDL has traded an average of 1.44M shares per day and 1505280 over the past ten days. A total of 96.78M shares are outstanding, with a floating share count of 92.75M. Insiders hold about 4.48% of the company’s shares, while institutions hold 80.85% stake in the company. Shares short for AVDL as of 1756425600 were 10484674 with a Short Ratio of 7.29, compared to 1753920000 on 10855121. Therefore, it implies a Short% of Shares Outstanding of 10484674 and a Short% of Float of 12.61.
Earnings Estimates
The dynamic stock of Avadel Pharmaceuticals plc (AVDL) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.1, with high estimates of $0.15 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.34 and $0.17 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is $0.73, with 6.0 analysts recommending between $1.14 and $0.49.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $73.58M this quarter.It ranges from a high estimate of $74.7M to a low estimate of $72.52M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.02MFor the next quarter, 10 analysts are estimating revenue of $78.05M. There is a high estimate of $80.14M for the next quarter, whereas the lowest estimate is $73.85M.
A total of 10 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $274.9M, while the lowest revenue estimate was $267.02M, resulting in an average revenue estimate of $272.27M. In the same quarter a year ago, actual revenue was $169.12MBased on 10 analysts’ estimates, the company’s revenue will be $356.12M in the next fiscal year. The high estimate is $378.3M and the low estimate is $333.7M.
